In the wake of COVID-19, government officials around the world face unprecedented decisions about when and to what extent they should reopen their respective societies before effective anti-viral medications or vaccines have been developed, necessary regulatory approvals obtained, and those solutions are manufactured for public use. Fundamentally, such decisions will require a delicate balance between protecting public health and facilitating economic growth, which, as we have all been reminded this year, are deeply intertwined.
Recent Posts
- Other Barks & Bites for Friday, April 11: CAFC Denies Transfer of EDTX Patent Case; Texas Leads Entire U.S. in IP Exports; and Google Declines to Respond to Cellspin Soft Cert Petition
- Federal Circuit Issues Precedential Order Denying Mandamus Relief for SAP, Despite District Court Errors
- CAFC Affirms Dismissal of Opposition to iVoters Marks But Hints USPTO Should Reconsider Registration
- Why Creativity and Ownership Are Crucial to Innovation | IPWatchdog Unleashed
- Can Judge Hughes Course Correct the CAFC on Prosecution Laches?